Synthetic immune niches for cancer immunotherapy

J. Weiden, J. Tel, C.G. Figdor

Research output: Contribution to journalReview articlepeer-review

110 Citations (Scopus)
597 Downloads (Pure)


Cancer immunotherapy can successfully promote long-term anticancer immune responses, although there is still only a limited number of patients who benefit from such treatment, and it can sometimes have severe treatment-associated adverse events. Compared with systemic immunomodulation, local immunomodulation may enable more effective treatment at lower doses and, at the same time, prevent systemic toxicity. Local delivery of engineered three-dimensional scaffolds may fulfil this role by acting as synthetic immune niches that boost anticancer immunity. In this Opinion article, we highlight the potential of scaffold-based adoptive cell transfer and scaffold-based cancer vaccines that, although applied locally, can promote systemic antitumour immunity. Furthermore, we discuss how scaffold-based cancer immunotherapy may contribute to the development of the next generation of cancer treatments.

Original languageEnglish
Pages (from-to)212-219
Number of pages8
JournalNature Reviews Immunology
Issue number3
Early online date30 Aug 2017
Publication statusPublished - 1 Mar 2018


  • Journal Article
  • Review


Dive into the research topics of 'Synthetic immune niches for cancer immunotherapy'. Together they form a unique fingerprint.

Cite this